Streetbeat News

Analyst Ratings

HUBS

Wolfe Research analyst Alex Zukin maintains an Outperform rating on HubSpot (HUBS) and raises the price target from $660 to $715.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 4:54 pm

GOLD

BMO Capital analyst Jackie Przybylowski maintains an Outperform rating on Barrick Gold (NYSE:GOLD) but lowers the price target from $26 to $24.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 4:42 pm

CRSP

Crispr Therapeutics (NASDAQ:CRSP) shares rose after Wolfe Research analyst Andy Chen initiated coverage with a Peer Perform rating. The stock has gained nearly 37% over the past month following FDA approval of its gene-edited cell therapy, Casgevy, for TDT in patients 12 and older. Additionally, Crispr announced a $280 million common shares sale to institutional investors at $71.50 per share, a premium over the 30-day volume-weighted average price. CEO Samarth Kulkarni highlighted the financing's role in supporting clinical trials and future programs.

Portfolio Pulse from Erica Kollmann

February 15, 2024 | 4:36 pm

WCN

BMO Capital analyst Devin Dodge has maintained an Outperform rating on Waste Connections (NYSE:WCN) and increased the price target from $166 to $178.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 4:31 pm

BAC

Deep-pocketed investors have shown a bearish sentiment towards Bank of America (NYSE:BAC), with a significant surge in options activity reported by Benzinga. The options scanner revealed 19 extraordinary activities, with a mix of bullish and bearish sentiments, but a higher inclination towards bearishness. The targeted price range for BAC is between $23.0 to $40.0. The largest trades include both calls and puts, with varying sentiments and strike prices. Bank of America, a major financial institution, is currently trading up by 2.25% at $33.88, with analysts setting an average price target of $45.5.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 4:30 pm

ACAD

Culper Research has issued a report on ACADIA Pharmaceuticals, titled 'ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Daybue In The Rearview'. The report likely contains analysis or findings that could impact investor perception and the stock's performance.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 4:20 pm